Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Semler Scientific Inc (SMLR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/01/2025: SMLR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -7.4% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 505.93M USD | Price to earnings Ratio - | 1Y Target Price 71 |
Price to earnings Ratio - | 1Y Target Price 71 | ||
Volume (30-day avg) - | Beta 1.43 | 52 Weeks Range 21.77 - 81.56 | Updated Date 06/29/2025 |
52 Weeks Range 21.77 - 81.56 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.39 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -60.69% | Operating Margin (TTM) -15.29% |
Management Effectiveness
Return on Assets (TTM) 4.18% | Return on Equity (TTM) -24.94% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 592336349 | Price to Sales(TTM) 10.28 |
Enterprise Value 592336349 | Price to Sales(TTM) 10.28 | ||
Enterprise Value to Revenue 12.03 | Enterprise Value to EBITDA 7 | Shares Outstanding 13141100 | Shares Floating 10076783 |
Shares Outstanding 13141100 | Shares Floating 10076783 | ||
Percent Insiders 12.03 | Percent Institutions 50.34 |
Upturn AI SWOT
Semler Scientific Inc
Company Overview
History and Background
Semler Scientific, Inc. was founded in 2007. It focuses on developing, manufacturing, and marketing products that help healthcare providers manage chronic diseases. The company has evolved from its initial product, QuantaFlo, to offering solutions for assessing and treating cardiovascular disease and related conditions.
Core Business Areas
- Peripheral Arterial Disease (PAD) Assessment: Semler Scientific's primary focus is on providing technology and solutions for the early detection and management of PAD. This includes the QuantaFlo system.
Leadership and Structure
Wayne T. Pan is the Chairman of the Board and CEO. The organizational structure includes departments for research and development, sales and marketing, and operations.
Top Products and Market Share
Key Offerings
- QuantaFlo: QuantaFlo is Semler Scientific's flagship product. It's a point-of-care test used to assess peripheral arterial disease (PAD) by measuring arterial blood flow. Exact market share data for QuantaFlo is difficult to ascertain; however, it's considered a significant player in the PAD diagnostic market. Competitors include companies offering Ankle-Brachial Index (ABI) testing equipment and other PAD diagnostic tools.
Market Dynamics
Industry Overview
The medical device industry is highly competitive and regulated. The market for diagnostic tools for cardiovascular diseases is growing due to the aging population and increasing prevalence of conditions like PAD.
Positioning
Semler Scientific is positioned as a provider of innovative, non-invasive diagnostic solutions for PAD. Its competitive advantage lies in the ease of use and efficiency of its QuantaFlo system.
Total Addressable Market (TAM)
The TAM for PAD diagnostics is estimated to be in the billions of dollars globally. Semler Scientific is focused on capturing a larger share of this market by expanding its product offerings and reaching new customer segments.
Upturn SWOT Analysis
Strengths
- Innovative product (QuantaFlo)
- Strong focus on PAD diagnostics
- Experienced management team
- High profit margins
Weaknesses
- Concentration of revenue from a single product
- Limited product diversification
- Dependence on Medicare reimbursement rates
- Relatively small company size
Opportunities
- Expanding into new geographic markets
- Developing new applications for QuantaFlo technology
- Acquiring complementary technologies or businesses
- Increasing awareness of PAD and the need for early diagnosis
Threats
- Competition from established medical device companies
- Changes in healthcare regulations and reimbursement policies
- Technological obsolescence
- Potential for product liability claims
Competitors and Market Share
Key Competitors
- IRMD
- BSX
- ABT
Competitive Landscape
Semler Scientific faces competition from larger, more established medical device companies. However, its focus on PAD diagnostics and its innovative QuantaFlo technology provide a competitive edge. Semler needs to expand product range to stay competitive.
Growth Trajectory and Initiatives
Historical Growth: Historical growth depends on actual historical data.
Future Projections: Future projections depend on the actual analyst estimates.
Recent Initiatives: Recent initiatives include expanding the sales force, investing in research and development, and exploring strategic partnerships.
Summary
Semler Scientific is a company focused on providing PAD diagnostic solutions with QuantaFlo as its flagship product. It has achieved strong financial performance due to its focus and innovative solution. However, the company's reliance on a single product is a weakness. Expansion into new markets and development of new products are necessary to drive future growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market conditions and company performance can change rapidly. Consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Semler Scientific Inc
Exchange NASDAQ | Headquaters Santa Clara, CA, United States | ||
IPO Launch date 2014-02-21 | CEO, President & Director Dr. Douglas Murphy-Chutorian M.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 79 | Website https://www.semlerscientific.com |
Full time employees 79 | Website https://www.semlerscientific.com | ||
Semler Scientific, Inc. provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. The company's products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, family practitioners, healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups and retailers. It offers its products through sales representatives and distributors. The company was incorporated in 2007 and is headquartered in Santa Clara, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.